Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database

Ingmar Wolff(Universitätsmedizin Greifswald), Sabine Brookman‐May(Ludwig-Maximilians-Universität München), Sascha Pahernik(Heidelberg University), Raphaela Waidelich(Ludwig-Maximilians-Universität München), Luigi Schips(University of Chieti-Pescara), Bernardo Rocco(Università Cattolica del Sacro Cuore), Luca Cindolo, Markus Hohenfellner(Heidelberg University), Ottavio De Cobelli(University of Milan), Richard Zigeuner(European Association of Urology), Andrea Tubaro(Sapienza University of Rome), L. Salzano(Azienda Ospedaliera G.Rummo), Christian G. Stief(LMU Klinikum), Kerry Madison(Washington University in St. Louis), I. Coman, Shahrokh F. Shariat(Universitätszahnklinik Wien), Georg C. Hutterer(Medical University of Graz), R. Sherburne Figenshau(Washington University in St. Louis), Giuseppe Lotrecchiano(Azienda Ospedaliera G.Rummo), Cosimo De Nunzio(Azienda Ospedaliera Sant'Andrea), B. Hoschke, Matthias May(Barmherzige Brüder Klinikum St. Elisabeth in Straubing), María del Carmen Santiago Martin(Hospital Universitario Príncipe de Asturias), M. Truß(Klinikum Dortmund), K. Miller(Charité - Universitätsmedizin Berlin), Orietta Dalpiaz, Bogdan Feciche, Manuel Sánchez‐Chapado(Hospital Universitario Príncipe de Asturias)
European Journal of Surgical Oncology
January 22, 2016
Cited by 57


Related Papers